AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

The following is a summary of “Bacteriophage therapy in women with chronic recurrent cystitis caused by multidrug-resistant bacteria: A prospective, observational, comparative study,” published in the ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

Columnist Teri Sforza writes that childhood obesity in California is on the rise, state data shows. Free school meals have ...

With overlooked reimbursement opportunities in the Payment-Driven Payment Model (PDPM) relatively common, nursing home ...